

# **RTOG 0236 Localization Study**













### Resource Center for Emerging Technologies

Radiation Oncology, University of Florida

QUALITY ASSURANCE REVIEW CENTER





### Status of RTOG 0236

Institution	RPC Acceptable	Letter Sent	Immobilization Acceptable	IRB	Patient Accrual
Cleveland Clinic Foundation	Yes	05/01/2006	Yes	07/01/2007	9
Duke University Medical Center	Yes	Pending			
Indiana University	Yes	12/30/2004	Yes	04/26/2007	13
Princess Margaret Hospital	Yes	12/30/2004	Yes	12/16/2007	13
Richard Roudebush VA Medical Center	Yes	Pending		05/25/2006	
Thomas Jefferson University	Yes	03/03/2005	Yes	07/19/2007	2
University of Florida	Yes	Pending		11/16/2005	
University of Rochester	Yes	11/07/2005	Took 1 <sup>st</sup> case off protocol	08/25/2007	1
University of Texas MD Anderson Cancer Center	Yes	12/23/2005	Yes	09/20/2007	1
University of Wisconsin Hospital	Yes	09/07/205	Waiting for 1 <sup>st</sup> case	08/20/2007	
UT Southwestern Medical Center	Yes	05/20/2005	Yes	09/19/2007	5
Virginia Commonwealth University	Yes	Pending			
Wake Forest University Health Sciences	Yes	Pending			
Washington University	Yes	12/30/2004	Yes	03/22/2007	15

**Total number of institutions = 14 (9 approved; 5 pending)** 





### RTOG 0438 Phase I Trial of Highly Conformal Radiation Therapy for Patients with Liver Metastases

SCHEMA						
All Patients will receive 10 fractions Monday-Friday for 2 weeks at the following levels; Dose escalation by 0.5 Gy to maximum of 50 Gy, as follows:						
Dose level Dose per fraction Total dose	<u>Level I</u> 3.5 Gy 35 Gy	† <u>Level II</u> 4.0 Gy 40 Gy	<u>Level III</u> 4.5 Gy 45 Gy	<u>Level IV</u> 5.0 Gy 50 Gy		
†Protocol Treatment Begins at Level II						





This QA process is aimed at demonstrating that the IGRT step is successful in positioning the target(s) relative to the treatment fields





# **Frame Transfer**




### RTOG Radiation Therapy Discology Group Cleveland Clinic – Abdominal Compression






### ITC Remote Review Tool







# Wash. Univ. (Port Films)







### Wash. Univ. (Port Films)







### Cleveland Clinic (BrainLAB)


#### Unregistered HyperCam 2







#### DRR Preview



Contrast	
Low	High
	[]

Vindowing		-						
VIILUUVVIILU	w	In	71		LA.	П	n	1
	w			U	22	4		

Enable




Adjust display parameters and press 'Next' to continue.






### **IMPAC FUSION**



Neatment: 1 19779 Flan Date: 10.01.2007 15:58:33.000 Flan Desorption: FLAN13 FLAN13



### **IMPAC FUSION**









### Cleveland Clinic (BrainLAB)


#### Unregistered HyperCam 2







DRR Preview



Contrast	
Low	High
	ŀ

Vindow	/IN (1
VIIIUUV	

Enable



Adjust display parameters and press 'Next' to continue.





### Status of RTOG 0438

Institution	RPC Acceptable	ITC Acceptable	Letter Sent	Notes	IRB	Patient Accrual
University of Rochester	Yes	Pending	10/12/2006		01/04/2008	
Princess Margaret Hospital	Yes	Yes	01/30/2006	6/2/06 passed 1 <sup>st</sup> case	10/21/2007	3
Cleveland Clinic Foundation	Yes	Pending	Pending		07/12/2007	



### Institution Approval Letter for RTOG – 0438

#### RTOG Radiation Therapy Oncology Group

Radiation Therapy

**Oncology Group** 

Date

, M.D. Institution – RTOG # ; NCI # ; RTF # Department of Radiation Oncology Address City, State, Zip

Dear Dr. :

Your institution has successfully completed the Liver Phantom Irradiation Dosimetry Test, Facility Questionnaire, Immobilization/Localization and Respiration Control Systems Test.

You can now enter patients on to RTOG Protocol 0438.

The Dry Run / Rapid Review will be reviewed on the actual case. The dosimetry will be reviewed and the study chair will determine if this and the drawn structures are protocol compliant and sufficient for the patient to go ahead with treatment. Since this test case (Dry Run / Rapid Review) is the first case entered from your institution, the scanning parameters, the structure outline, and the dosimetry will have to be according to protocol in order to pass the Dry Run / Rapid Review PRIOR TO DELIVERING ANY PROTOCOL TREATMENT. The plan will be reviewed centrally at the ITC, and suggestions regarding protocol compliance will be forwarded to your institution. The treatment plan for subsequent patients enrolled from your site will not be required to be centrally reviewed prior to treatment, but will be reviewed for protocol compliance at a later date.

However, the Immobilization/Localization and Respiration Control Systems Test must be repeated for the first 2 cases submitted from your institution and the results reviewed by James Galvin, D.Sc., Medical Physics Co-Chair. The data for the first patient entered must be reviewed and approved before you enter a second patient, and the results of the Immobilization/Localization and Respiration Control Systems Study for this patient must be approved prior to entering a third patient. At this point, any additional number of patients can be entered. You will have to send forward the results of the Immobilization/Localization and Respiration Control Systems Study for the third and fourth patients entered. Please refer to the attached information.

Sincerely,

Elizabeth A. Martin Director, R.T. Quality Assurance

cc: Physicist Research Associate James Galvin, D.Sc. RTOG Randomization ITC RPC



1818 Market Street - Suite 1600, Philadelphia, PA 19103 www.rtog.org

(215) 574-3189 or (800) 227-5463, ext. 4189

#### RTOG Protocol 0438

#### Immobilization/Localization and Respiration Control Systems Study

This study must be performed on a single patient, and approval received from RTOG Headquarters, before you attempt to enter your first patient on RTOG Protocol 0438. A similar study must be performed for the first patient entered on this protocol, and approval must be received from Headquarters prior to entering a second patient. This same procedure must be followed before entering a third patient. However, once approval has been given to enter the third patient on the protocol, no additional Immobilization/Localization data needs to be gathered.



Supported by the Division of Cancer Treatment and Diagnosis, National Cancer Institute

a leader in defining more effective cancer therapies